BACKGROUND: Waning of vaccine-induced immunity is considered to play a central role in the reemergence of mumps among vaccinated young adults. The aim of the present study was to investigate antibody responses and safety of a third dose of measles-mumps-rubella vaccine (MMR-3) in 150 young adults. Antibody levels were related to a surrogate of protection based on preoutbreak serum antibody levels in 31 persons with and 715 without serological evidence of mumps. METHODS: Mumps virus-specific immunoglobulin G (IgG) antibody responses and mumps virus-neutralizing antibody responses (based on the focus-reduction neutralizing test) against both the Jeryl Lynn mumps virus vaccine strain (hereafter, the "vaccine strain") and the MuVi/Utrecht.NLD/40.10 outbreak strain (hereafter, the "outbreak strain") were determined, and vaccine safety was evaluated. RESULTS: Four weeks following MMR-3 receipt, levels of IgG, anti-vaccine strain, and anti-outbreak strain antibodies increased by a factor of 1.65, 1.34, and 1.35, respectively. Although antibody levels decreased 1 year later, they were still above the baseline level by a factor of 1.37, 1.15, and 1.27, respectively. Based on the surrogate protective antibody cutoff, significantly more participants were protected against mumps virus infection up to 1 year after vaccination (ie, they had antibody levels above the presumed threshold for herd immunity). CONCLUSIONS: MMR-3 receipt increased antibody levels that may protect against mumps virus infection for longer than previously assumed and is expected to be a good and safe intervention for controlling a mumps outbreak. CLINICAL TRIALS REGISTRATION: 2016-001104-36; NTR5911.
BACKGROUND: Waning of vaccine-induced immunity is considered to play a central role in the reemergence of mumps among vaccinated young adults. The aim of the present study was to investigate antibody responses and safety of a third dose of measles-mumps-rubella vaccine (MMR-3) in 150 young adults. Antibody levels were related to a surrogate of protection based on preoutbreak serum antibody levels in 31 persons with and 715 without serological evidence of mumps. METHODS:Mumps virus-specific immunoglobulin G (IgG) antibody responses and mumps virus-neutralizing antibody responses (based on the focus-reduction neutralizing test) against both the Jeryl Lynn mumps virus vaccine strain (hereafter, the "vaccine strain") and the MuVi/Utrecht.NLD/40.10 outbreak strain (hereafter, the "outbreak strain") were determined, and vaccine safety was evaluated. RESULTS: Four weeks following MMR-3 receipt, levels of IgG, anti-vaccine strain, and anti-outbreak strain antibodies increased by a factor of 1.65, 1.34, and 1.35, respectively. Although antibody levels decreased 1 year later, they were still above the baseline level by a factor of 1.37, 1.15, and 1.27, respectively. Based on the surrogate protective antibody cutoff, significantly more participants were protected against mumps virus infection up to 1 year after vaccination (ie, they had antibody levels above the presumed threshold for herd immunity). CONCLUSIONS: MMR-3 receipt increased antibody levels that may protect against mumps virus infection for longer than previously assumed and is expected to be a good and safe intervention for controlling a mumps outbreak. CLINICAL TRIALS REGISTRATION: 2016-001104-36; NTR5911.
Authors: Patricia Kaaijk; M Alina Nicolaie; Debbie van Rooijen; Marianne A van Houten; Fiona R van der Klis; Anne-Marie Buisman; Rob S van Binnendijk Journal: Open Forum Infect Dis Date: 2020-10-20 Impact factor: 3.835
Authors: Regnerus A Vos; Liesbeth Mollema; Rob van Binnendijk; Irene K Veldhuijzen; Gaby Smits; Alcira V A Janga-Jansen; Sharda Baboe-Kalpoe; Koen Hulshof; Fiona R M van der Klis; Hester E de Melker Journal: Vaccines (Basel) Date: 2019-10-01
Authors: Patricia Kaaijk; Maarten E Emmelot; Jeroen Kerkhof; Cécile A C M van Els; Hugo D Meiring; Jelle de Wit; Rogier Bodewes Journal: Vaccines (Basel) Date: 2021-06-25
Authors: Adam V Wisnewski; Jian Liu; Carolina Lucas; Jon Klein; Akiko Iwasaki; Linda Cantley; Louis Fazen; Julian Campillo Luna; Martin Slade; Carrie A Redlich Journal: PLoS One Date: 2022-01-18 Impact factor: 3.240
Authors: Patricia Kaaijk; Alienke J Wijmenga-Monsuur; Hinke I Ten Hulscher; Jeroen Kerkhof; Gaby Smits; Mioara Alina Nicolaie; Marianne A van Houten; Rob S van Binnendijk Journal: Vaccines (Basel) Date: 2022-01-17